SV joins CRUK on a $250M-plus fund with an eye on de­vel­op­ing new can­cer drugs

With its de­men­tia fund up and run­ning, SV Health In­vestors is kick­start­ing a new, spe­cial­ized $250 mil­lion-plus fund to gam­ble on new can­cer biotechs — dou­bling down on one of the hottest fields in bio­phar­ma. And they’re do­ing it with a big con­tri­bu­tion from Can­cer Re­search UK to help seed the ef­fort.

CRUK is con­tribut­ing $25 mil­lion to the cause, and open­ing some doors for SV along the way. The non-prof­it re­search group has a pipeline of 30 drugs it’s col­lab­o­rat­ing on in pre­clin­i­cal or clin­i­cal de­vel­op­ment, build­ing on the 8 ap­proved ther­a­pies that have helped fu­el its sci­en­tif­ic mis­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.